There is a completely different perspective email today from [email protected] about Viraleze being “nasal hygiene” no mention of covid, which parallels the description of Nasodine in its US launch this month. Is the new direction a strategy to launch without seeking FDA approval in the US and compete with Nasodine. Two Australian products with greater efficacy than Paxlovid but great for all respiratory viruses - which have been given terrible treatment in Australia - their country of origin.
There is a completely different perspective email today from...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.20M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.8¢ | $67.06K | 673.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 150305 | 9.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 21082 | 2 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
10.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 10.0¢ | 10.5¢ | 9.8¢ | 355338 | ||
| Last updated 14.59pm 07/06/2024 ? | |||||
| SPL (ASX) Chart |